Germany – Pharmaceutical products – Conclusion not excluding drug discount agreement. according to Section 130a Paragraph 8 SGB V through an open house model for the active ingredient Aflibercept DFL (ATC code according to WHO: S01LA05; except 114.3 mg/ml)
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for medicines with the active ingredient aflibercept as an injection solution in a vial (ATC code according to WHO: S01LA05; except 114.3 mg/ml). The contract is concluded within the framework of a so-called open house model, i.e. h. The conclusion of a contract is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations are not possible